Augustine Therapeutics, a Leuven, Belgium-based biotechnology company focused on developing new therapies through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, raised EUR 77.7M in Series A funding.
The round was co-led by Novo Holdings and Jeito Capital with participation from Asabys Partners, who led an initial EUR 17.5M closing in 2024, Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital.
The company intends to use the funds to advance its lead candidate, AGT-100216, through a Phase I/II proof-of-concept clinical trial in CMT.
Led by CEO Gerhard Koenig, Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, neurodegenerative and cardio-metabolic diseases through its approach to selectively inhibit HDAC6. Its lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth (CMT) disease. With its non-hydroxamate, non-hydrazide producing chemotype, the HDAC6 approach is selective, avoids the limitations of other chemotypes, and built for chronic diseases.
It was founded on the research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium.
FinSMEs
24/03/2025